论文部分内容阅读
目的:讨论分析晚期肝癌患者应用靶向药物进行治疗的效果。方法:选择2015年5月至2016年5月于我院就诊的晚期肝癌患者126例,将126例晚期肝癌患者按照1∶1的比例平均分为两组,即分为实验组63例晚期肝癌患者为一组,参考组63例晚期肝癌患者为一组。实验组63例晚期肝癌患一律选择靶向药物配合化疗法进行相关治疗,而参考组63例晚期肝癌患者则一律选择单纯化疗法进行相关治疗。统计分析两组患者治疗后血清甲胎蛋白(AFP)水平的改变状况,并将统计分析的两组数据进行组间对比。结果:实验组63例患者的AFP整体下降率为76.19%,高于常规组63例患者的AFP整体下降率为46.03%,差异性显著。结论:相对单纯化疗法治疗而言,向药物配合化疗法在晚期肝癌患者中的应用效果更为有效,并且患者的耐受性更为良好,具有临床推广价值。
OBJECTIVE: To discuss and analyze the effect of targeted drug therapy in patients with advanced liver cancer. Methods: From May 2015 to May 2016, 126 patients with advanced hepatocellular carcinoma (HCC) treated in our hospital were selected. One hundred and sixty-six patients with advanced HCC were divided equally into two groups according to the ratio of 1: A group of patients, the reference group of 63 patients with advanced liver cancer as a group. Sixty-three patients with advanced hepatocellular carcinoma in the experimental group were treated with targeted drugs in combination with chemotherapy, whereas 63 patients with advanced hepatocellular carcinoma in the reference group were treated with chemotherapy alone. The changes of serum AFP levels in both groups were statistically analyzed and compared between the two groups. Results: The overall AFP decline rate of 63 patients in the experimental group was 76.19%, which was significantly higher than that in the conventional group (63.03%). The overall AFP decline rate was 46.03%. Conclusion: Compared with chemotherapy alone, the drug combination chemotherapy is more effective in patients with advanced liver cancer, and the patients are more tolerant and have clinical value of popularization.